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Accepted 15 October 2020; Published online 21 October 2020AbstractObjectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions
against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of
timing related to the course of the COVID-19 epidemic and research question evaluated.
Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Plat-
form. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and
created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered.
Results: ByAugust 12, 2020, 1,568 trials for COVID-19were registeredworldwide. Overall, themedian ([Q1eQ3]; range) delay between
the first case recorded in each country and the first RCT registered was 47 days ([33e67]; 15e163). For the 9 countries with the highest number
of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials
evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254
trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients.
Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in
research questions. Most trials were registered when the first peak of the pandemic has passed.  2020 The Author(s). Published by Elsev-
ier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Key findings
 Most of clinical trials of COVID-19 are planned af-
ter the peak of the epidemic.
 These trials are mainly single-centered, open-
labeled, and have relatively small sample size.
 There is a notable redundancy in research
questions.
What this study adds?
 We have created a living mapping that visualizes
all clinical trials of COVID-19.
 The living mapping supports researchers and deci-
sion makers in identifying research gaps, thus plan-
ning research of high priority.
What is the implication and what should change
now?
 Research community needs a better coordination in
research planning to ensure that all potential treat-
ments for COVID-19 are evaluated with robust
methodology.
 The living mapping provides a tool to monitor sta-
tus of research and enhance research collaboration
and interaction in medical and scientific commu-
nity to avoid research waste.1. Introduction
In December 2019, an outbreak of pneumonia caused by
a novel coronavirus started in Wuhan, Hubei Province in
China. The disease was later determined to be SARS-
CoV-2 infection or coronavirus disease 2019 (COVID-19)
[1]. In early March 2020, the disease had spread to more
than 100 countries and territories [2]. On March 12,
2020, the World Health Organization (WHO) declared the
outbreak a pandemic [3]. To respond to this emergency, re-
searchers all over the world began to actively engage in
research activities to develop and evaluate preventive and
therapeutic agents for COVID-19.
Given this unprecedented context, we aimed to inform
decision makers and researchers in near real-time about
current research efforts, research gaps, and overlap. A map-
ping of all research efforts is imperative to support re-
searchers and decision makers to monitor status of
research response to the epidemic and integrate emerging
evidence in research planning timely to ensure that all po-
tential treatments are evaluated, while avoiding waste in re-
sources invested. For this purpose, we performed a living
mapping of all registered randomized controlled trials(RCTs) investigating interventions to prevent and treat
COVID-19. This living mapping is updated every week,
and the results are publicly available at https://covid-nma.
com/.
This article describes the planning of RCTs in terms of
timing related to the course of the pandemic and research
questions.2. Methods
This mapping is part of the COVID-NMA project, which
also includes living systematic reviews and living network
meta-analyses of studies of COVID-19 [4,5]. The protocol
of this project is available at https://zenodo.org/record/
3903347#.XwLasUBuI2x.
2.1. Data sources
Our data are obtained from the WHO International Clin-
ical Trials Registry Platform (ICTRP) (https://www.who.
int/ictrp/en/), an international registry that assembles infor-
mation on clinical trials registered in 17 primary registries
[6]. The WHO ICTRP has created a database dedicated to
all clinical trials evaluating interventions to prevent and
treat COVID-19. The database is updated weekly and is
publicly available.
2.2. Eligibility criteria
Whenever the database is updated, we use Hypertext
Preprocessor (PHP) programming language to identify
studies that are newly registered in the database. Two re-
searchers (VN and GF) systematically search the platform
every week to identify new eligible RCTs for data extrac-
tion. All RCTs assessing the efficacy and safety of interven-
tions for preventing or treating COVID-19 and patients in
the postacute period are included.
We exclude observational studies, case series, and non-
randomized or single arm studies (i.e., diagnostic test
studies). We also exclude studies (1) evaluating interven-
tions to reduce psychological distress caused by the
COVID-19 outbreak or (2) assessing herbs, homeopathy
therapy, and traditional Chinese medicine (TCM) (with on-
ly TCM in two groups or TCM plus standard of care).
2.3. Data extraction
A standardized data collection form is used to collect
data describing the RCTs. Several data items are available
from the WHO ICTRP database, such as registration num-
ber, countries where trials are conducted, recruitment sta-
tus, inclusion and exclusion criteria, primary outcomes,
and sample size. A team of 11 trained data collectors inde-
pendently retrieve other information from the trial registra-
tion such as study aim, number of arms, type of
participants, and information related to experimental
Table 1. Characteristics of registered COVID-19 trials in the WHO
International Clinical Trials Registry Platform at the time of





North America 324 (21)
Latin America 114 (7)
Africa 73 (5)
Oceania 23 (2)
Multiple regions 52 (3)
Not reported 48 (3)
Recruitment status






With results available 32
Number of centers
Single center 735 (47)
Multiple centers 638 (41)









Open label 706 (45)
Blinded label 798 (51)
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ment type). Two researchers (VN and GF) verify the quality
of the data and ensure the consistency of data entered in the
database.
We classify study aims as evaluation of prevention inter-
ventions, COVID-19 treatments, and postacute period inter-
ventions. In RCTs evaluating preventive interventions,
participants are classified as healthy volunteers, health
workers, and high-risk patients. Patients in RCTs assessing
COVID-19 treatments are classified by disease severity
(i.e., mild, moderate, severe, and critical). Clinical criteria
for classifying disease severity are provided in Appendix
1. The full list of treatment types is provided in
Appendix 2.
2.4. Monitoring the recruitment status
When the database of the WHO ICTRP is updated every
week, we use PHP programming language to identify RCTs
with changes in recruitment status (e.g., from not recruiting
to recruiting) and update our database accordingly.
2.5. Data on the course of the epidemic
The COVID-19 database maintained by Our World in
Data (https://ourworldindata.org/coronavirus-source-data)
was used to visualize the evolution of the pandemic over
time. The database is updated daily and includes the num-
ber of confirmed cases, deaths, and testing data. We consid-
ered only data related to the number of confirmed cases and
deaths.
2.6. Data analysis
We created an online interactive mapping tool to visu-
alize the data of trials registered. The interactive mapping
was developed with D3.js [7] as an Observable notebook
[8]. The projection for the map used was implemented in
JavaScript [9]. We also used time series plotting to visu-
alize the evolution of COVID-19 research over time. This
visualization was performed in R v3.4.2 (the R Foundation
Statistical Computing, Vienna, Austria).Postacute period care 12 (1)
Sample size, median
Trials evaluating preventive interventions 540 (200e1,600)
Trials evaluating treatment 100 (60e269)
Trials evaluating postacute period
interventions
100 (60e121)
Data are n (%) or median (Q1eQ3).3. Results
3.1. General characteristics of the registered COVID-19
RCTs
Up to August 12, 2020, there were 4,956 studies regis-
tered on the WHO ICTRP; 1,568 were RCTs, of which
878 (56%) were recruiting. Overall, 35 trials were
completed; only 4 trials gave access to the results. In our
database, 735 (47%) trials are single-center. Trials are be-
ing conducted in Asia (32%), Europe (28%), and North
America (21%). Most trials use a parallel study design
(91%) and 705 (45%) an open-label design (Table 1). Most
trials (n 5 1,333; 85%) focus on interventions for treatingCOVID-19. Only 223 (14%) consider prevention, and only
12 (0.8%) evaluate postacute period care. The median
([Q1eQ3]; range) sample size is 540 ([200e1,600];
30e130,000) for trials evaluating prevention and 100
([60e269]; 10e12,000) for those evaluating treatment.
Overall, 52 trials are conducted in multiple regions.
Table 2. Sample size of registered COVID-19 trials in countries with the highest number of COVID-19 cases at the time of analysis
Country Number of trials registered Median sample size Number of trials with more than 100 patients per arm
United States 238 103 (50e300) [10e10,000] 86 (36)
China 160 90 (58e160) [12e520] 35 (22)
Iran 140 60 (40e100) [10e3,000] 11 (8)
Spain 93 104 (60e200) [18e3,040] 25 (27)
France 78 189 (100e428) [20e3,140] 36 (46)
United Kingdom 42 275 (64e471) [20e12,000] 22 (52)
Italy 30 162 (100e376) [50e2,712] 10 (33)
India 47 100 (45e183) [20e1,500] 10 (21)
Brazil 44 196 (84e446) [30e1,968] 21 (48)
Data are n (%) and median (Q1eQ3) [range].
110 V.T. Nguyen et al. / Journal of Clinical Epidemiology 130 (2021) 107e116The interactive map (https://covid-nma.com/dataviz/#)
allows users to interact with data by selecting different pa-
rameters such as locations, severity of patients included in
trials, and type of treatment evaluated to visualize all
studies of interest.
In certain countries, the sample size is relatively small
for trials evaluating COVID-19 treatments (Table 2). In
the United States, the country with the highest number of
trials registered, 113 (47%) trials have less than 50 patients
per trial arm and 86 trials (36%) have more than 100 pa-
tients per trial arm. In China, 86 trials (54%) have less than
50 patients per arm and 35 trials (22%) with more than 100
patients per arm. In Europe, Spain registered the highest
number of trials with 39 trials (42%) having less than 50
patients per arm and 25 trials (27%) having more than
100 patients per arm. By contrast, in the United Kingdom,
52% (22/42) of trials have more than 100 patients per arm.Fig. 1. Registered trials of COVID-19 over time in countries3.2. Timing of research response to the evolution of the
pandemic
Fig. 1 represents a strip plot of all registered RCTs over
time in terms of the first confirmed case for each country.
The interactive version of this figure (https://covid-nma.
com/research_delay/) allows for representing and aligning
trial registration by the first confirmed case, the 100th
confirmed case, the first death, and the 10th death. Overall,
the median ([Q1eQ3]; range) delay between the first case
recorded in each country and the first RCT registered was
47 days ([33e67]; 15e163). Similarly, the median
([Q1eQ3]; range) delay between the first death and first
trial registered was 21 days ([11e38]; 7 to 108).
Fig. 2 shows the number of registered trials evaluating
COVID-19 treatment overtime, the cumulative number of
patients to be recruited and the number of new COVID-with more than 50,000 confirmed COVID-19 cases.
Fig. 2. Expected sample size in registered trials evaluating COVID-19 treatments in comparison with the evolution of the epidemic in each country
(only single-country trials are presented ).
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of trials registered at the time of analysis. This figure does
not consider multinational trials because the expected num-
ber of patients to be recruited in each country is not
available.
Overall, the cumulative expected sample size for all tri-
als evaluating COVID-19 treatment was 378,649 patients.
In the United States, 90/238 (38%) trials were registered
before the first epidemic peak (i.e., April 26, 2020), repre-
senting 44% of the total number of patients to be recruited
in all trials. In China, 41/160 (26%) trials were registered
before the peak (i.e., February 13, 2020), representing
33% of the total number of patients to be recruited in all
trials. In Europe, Spain registered only 2/93 trials (2%)
before the peak (i.e., March 27, 2020). In France, the first
trial was registered only 8 days before the peak (i.e., April
01, 2020). Eight trials (10%) registered before the peak in
France accounted for 28% of the total number of patients
to be recruited in all trials. In the United Kingdom, 6/42
(14%) trials were registered before the peak (i.e., April
12, 2020), representing 40% of the total number of patients
to be recruited in all trials. In Italy, no trial was registered
before the peak on March 22, 2020.3.3. Research questions and interventions evaluated
3.3.1. Trials evaluating preventive interventions
In our database, among 223 trials evaluating preventive
interventions, the most common chemoprophylaxis evalu-
ated is antimalaria drugs (68 [36%] trials; 62 assessing hy-
droxychloroquine as monotherapy expecting to recruit
93,267 participants and 6 assessing chloroquine as mono-
therapy expecting to recruit 136,770 participants). In total,
89 trials are evaluating different types of vaccines; 27 eval-
uate Bacille Calmette-Guerin vaccine to prevent COVID-
19, and 52 trials evaluate vaccines specifically developed
for coronavirus.3.3.2. Trials evaluating COVID-19 treatments
Overall, 1,333 trials evaluating COVID-19 treatments
are evaluating antimalaria drugs (254 trials, 19%), different
regimes of antivirals (236 trials, 18%), and monoclonal an-
tibodies (133 trials, 10%). Fig. 3 shows the evolution over-
time of the 8 most evaluated therapeutic agents. In the
interactive mapping version, users are able to select the
number of therapeutic agents to be shown, countries, and
number of trials evaluating each treatment or expected
Fig. 3. Cumulative number of registered COVID-19 trials and patients planned to be recruited over time for the 10 most commonly assessed ther-
apeutic agents.
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of trials evaluating hydroxychloroquine increased greatly.
Up to August 12, 2020, 142 trials worldwide were planned
to assess hydroxychloroquine, with an expected sample size
of 34,080. Lopinavir/ritonavir is the second most common
agent evaluated, with 48 trials and an expected sample size
of more than 12,734, followed by tocilizumab, with 41 tri-
als and an expected sample size of 6,121. In total, 28 trials
are planned to evaluate remdesivir with 7,365 patients.
Fig. 4 presents the 8 most evaluated therapeutic agents
in 6 countries. In our database, hydroxychloroquine is the
most commonly tested agent across these countries, and tri-
als evaluating different regimes of hydroxychloroquine
expect to involve the highest number of patients. In Brazil,
15/44 trials are evaluating different regimes of hydroxy-
chloroquine and expect to recruit 4,121 patients, represent-
ing 28% of all expected patients to be recruited in Brazil at
the time of analysis (14,805 patients). In France, 6,003 pa-
tients are expected to be recruited in trials of hydroxychlor-
oquine, representing 20% of all expected number of
patients to be recruited (30,079 patients). In the United
States, 9,325 patients are expected to be recruited in trialsof hydroxychloroquine, representing 14% of all expected
number of patients to be recruited (70,596 patients).
Fig. 5 represents a mapping of trials evaluating the five
most frequently tested treatments in regard to severity of
patients recruited in trials and types of comparators.4. Discussion
4.1. Summary of findings
Our living mapping of RCTs of prevention and treat-
ment of COVID-19 shows a substantial waste of research
because of lack of coordination and collaboration in the
research response to the pandemic. While WHO and Euro-
pean Medicines Agency called for efforts to prioritize large,
multicenter, and multiarm trials to provide meaningful and
interpretable evidence, most trials registered had only a sin-
gle center involved and a relatively small sample size [10].
Although research community have had responded to the
epidemic at an unprecedented rate to set up trials rapidly
after the first confirmed case, our mapping shows that many
trials across different countries were planned when the first
Fig. 4. Cumulative number of expected patients in registered COVID-19 trials evaluating therapeutic agents in 6 countries with the highest number
of COVID-19 trials registered.
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tients to be recruited are expected to come from trials regis-
tered after the first peak of the epidemic. This situation is
particularly problematic because the time frame for
including patients is quite short, only a few weeks during
the epidemic. Trials registered when the epidemic has
wound down might not succeed in recruiting a large enough
sample for a clear conclusion. At the time of this analysis,
no trial in France, Spain, and Italy had released official re-
sults, which might reflect the difficulties in recruitment due
to the late recruitment during the first peak. Furthermore,
trial results will probably be published after the epidemic
has passed, and countries where the trials were conducted
might not have the direct benefits to improve clinical prac-
tice at the time of the epidemic [11e15].
The planning of trials in response to COVID-19 has a
notable redundancy in research questions. In March 2020,
hydroxychloroquine received tremendous attention after
the results of an observational study in France were pub-
lished that generated a huge debate [16]. After this publica-
tion, the US president highlighted this treatment as being a
‘‘game changer,’’ despite the lack of consistent data fromRCTs [17]. On March 28, 2020, the US Food and Drug
Administration approved hydroxychloroquine for treating
COVID-19 [18]. Just after this, the number of trials evalu-
ating different regimens of hydroxychloroquine increased
markedly, with the number of patients expected to be re-
cruited representing 10% of the total number of patients
to be recruited in all trials registered. This massive concen-
tration of research efforts for one therapeutic agent not only
competes with research examining other hypotheses for
scarce resources but also impairs recruitment in trials eval-
uating other potential treatments [19]. The second most
frequently evaluated treatment was lopinavir/ritonavir, with
39 trials representing 4% of the patients to be included in
trials of COVID- 19 treatment. Nevertheless, a large
RCT, RECOVERY, conducted in the United Kingdom,
showed no beneficial effect of hydroxychloroquine or lopi-
navir/ritonavir [11]. The WHO recently decided to discon-
tinue the hydroxychloroquine and lopinavir/ritonavir arms
of the Solidarity trial after the interim results were commu-
nicated [20]. Indeed, clinical trials need to be replicated in
different settings to have confidence in the results. Howev-
er, the number of trials planned was disproportionate to the
Fig. 5. Mapping of the five most frequently evaluated treatments.
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hydroxychloroquine and lopinavir/ritonavir would likely be
wasted.4.2. Implications
For many emerging infectious diseases such as COVID-
19, the time when the epidemic occurs is the only opportu-
nity to conduct research and generate evidence about the ef-
ficacy of therapeutic treatments and preventive
measurements. This mapping shows that many COVID-19
trials might have missed the first peak of the pandemic.
This issue reflects the challenges that researchers might
encountered in planning and conducting trials under a com-
plex context of the pandemic. At the early stage of the
pandemic, there was limited data on potential treatments
to be evaluated in a trial, no core outcome set available
for COVID-19 to guide the selection of outcome. Logistical
challenges in producing placebo might also influence the
choice of trial design. Further, finding trial personnel is
not an easy task as clinicians and nurses are overburdened
with patient care. Although multicentered trials could help
to increase recruitment rates, obtaining funding, regulatory,and ethical approvals from multiple sites could be chal-
lenging in the context of the pandemic, which delayed
the process. However, the lesson from previous epidemics
such H1N1 and Ebola highlighted the importance of start-
ing and completing trials during the peak of the epidemic
to ensure successful recruitment and provide evidence
timely to patient care. To overcome logistic and methodo-
logical challenges, the two large trials RECOVERY and
Solidarity used relatively simple protocol with a straightfor-
ward outcome of all-cause mortality to reduce burden of
data collection. The RECOVERY trial successfully used a
robust adaptive design to test a range of different treatment
options with minimized administrative tasks to avoid
burdening the health care system. Collaboration between
researcher centers to boost recruitment plays a crucial role
in addressing the fast evolution of the epidemic. The RE-
COVERY trial with a network of 175 hospitals in the
United Kingdom rapidly enrolled thousands of patients to
provide evidence on effectiveness of hydroxychloroquine
and dexamethasone to the medical community [11,21].
With the scarcity of research resources, we must coordinate
research efforts, identify gaps that need further research and
ensure that all promising treatments are being evaluated
115V.T. Nguyen et al. / Journal of Clinical Epidemiology 130 (2021) 107e116[22]. National regulatory bodies, ethical review boards and
funders should prioritize and facilitate the conduct of large,
multicenter, and multiarm trials. Regulatory and health au-
thority should provide timely guidance to clinicians to
avoid off-label drug uses based on anecdotal evidence
which might cause difficulties to trial planning and recruit-
ment [23,24].
This study highlights the importance of clinical trial reg-
istries, an underused resource, to monitor the state of
research for improving the organization of research efforts
[25e27]. Our interactive living mapping of COVID-19
research was designed to help decision makers use data
from clinical registries for an up-to-date picture of all
research questions being investigated so as to prioritize
research and avoid waste in research [28]. Furthermore, this
interactive mapping tool might also enhance collaboration
in research to reduce redundancy and competition in trial
organization [19,29].
4.3. Limitations
In this analysis, we visualized trial registration over time
by using the registration date rather than the actual starting
date of recruitment because the ICTRP database did not
distinguish the actual starting date from the expected starting
date for each trial. In addition, investigators might not regu-
larly update the status of recruitment on trial registries. For
example, the trial ChiCTR2000029544 was reported as
‘‘Not recruiting’’ on the registry, but the results of the trial
were published [30]. Furthermore, the structure of reporting
is heterogeneous across the primary registries, which affects
the quality of reporting [31]. Investigators might register one
trial in more than one registry under different titles or inves-
tigator names, such duplicates are almost systematically de-
tected by the ICTRP while a very few may remain
undetected. Finally, we did not assess the risk of bias for each
trial registered as information in trial registration is inade-
quate to enable a comprehensive assessment.5. Conclusions
We have created a living mapping tool to keep track of
the evolution of research on COVID-19 for supporting de-
cision makers in prioritizing and planning research. This
mapping analysis showed that many COVID-19 trials were
registered after the first peak had passed and a need to
improve the organization of research efforts to avoid
research redundancy. Visualizing ongoing research can
enhance the collaboration and interaction between research
communities that can go beyond the COVID-19 crisis.Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jclinepi.2020.10.010.References
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